Bill Schmick | The Retired Investor: Investors eye prospects for marijuana companies

Don't miss the big stories. Like us on Facebook.  

It has been two years since marijuana companies fell into a pothole of investor disillusionment. Stock prices, valuations and even some company managements have disappeared down that dark hole. Some investors are betting that the time is right to get back in.

During the peak mania for marijuana stocks, I warned readers that while I thought the long-term prospects for the marijuana industry were positive, valuations had reached impossible levels. That proved to be an accurate analysis.

Since then, all the pie-in-the-sky forecasts of industry enthusiasts failed to materialize, leaving in their wake a trail of lower sales, and disappointing or nonexistent earnings. An increasing need for cash and financing by company managements that promised too much and delivered too little severally hampered the industry.

In several instances, as their stock prices plummeted by well over 100 percent, managements resigned or were forced out. And then the coronavirus pandemic hit.

As the true extent of the coronavirus became known, pot stocks, in the minds of investors, were divided into two groups: those that had money in the bank and were deemed to be able to weather the storm, and those that were not. In March, as governments in the U.S. and Canada (where the largest marijuana companies are located) locked down their economies, there was a sudden surge and unexpected demand for marijuana.

Article Continues After Advertisement

For those using medical marijuana, it was largely a reflex "stock up" phenomena (like toilet paper or disinfectants). Recreational users of pot also increased their purchases. For many, it was a means of making the stay-at-home orders a bit more bearable.

Article Continues After These Ads

As lockdowns lessened and marijuana stores reopened to in-store sales on both sides of the borders, revenues continued to increase, at least in Canada.

However, with the exception of two companies, Canopy Growth and Cronos Group, few companies can claim that they are out of the woods financially. The fact that two mega-companies, Constellation Brands and Altria, have taken major stakes in those two companies explains their above-average cash cushions and financial strength. Yet, investors hoping for future clues to the health of the overall industry based on their recent earnings results were, at best, confused. In August, Cronos announced disappointing results, while Canopy beat estimates.

About the best one can say for pot stakes from recent price action is that they have stopped going down. Technical analysts would call their present pattern a "consolidation phase after a sharp decline." It is a period where the last bull market babies in these stocks finally sell, take their losses and move on. So, what's next for the group?

Article Continues After Advertisement

The catalyst most bulls are waiting for is the November elections. The story they are spinning is that, regardless of who wins, legislation to legalize marijuana at the federal level will be passed sometime during the next election cycle. Whether that will include medical, as well as recreational, marijuana, is a big question mark.

Recreational use is thought to be the easier legislation to pass, since it largely circumvents the Food and Drug Administration and the myriad rules and regulatory hoops that would beset the pharmaceutical use of marijuana. In anticipation of that event, cannabis companies are planning mergers and acquisitions. They hope to enhance their existing brands and develop distribution chains into some of the more underserviced sections of the U.S. market. That is a more doable strategy now that stock valuations are at more realistic levels.

Of course, the other long-standing "story" behind many of these fledgling pot stocks is that once marijuana is finally legalized in the United States, the big guns in the food and agricultural sectors will suddenly descend on the sector and gobble up all the little guys. I guess, from an investor's point of view, the difference in investing now on these same story stocks is that you are no longer buying them at nosebleed levels. For some who are willing to wait, that might be a good bet.

Bill Schmick is registered as an investment adviser representative of Onota Partners Inc. in the Berkshires. He can be reached at 413-347-2401, or e-mail him at


If you'd like to leave a comment (or a tip or a question) about this story with the editors, please email us. We also welcome letters to the editor for publication; you can do that by filling out our letters form and submitting it to the newsroom.

Powered by Creative Circle Media Solutions